遗传学在识别乳腺癌低风险女性中的潜在价值
该回顾性病例对照研究纳入健康内华达项目2018至2022年测序的25591名女性,评估低遗传风险组与平均风险组的乳腺癌发病率和发病年龄。低风险组乳腺癌诊断风险显著降低(HR 0.39;95%CI 0.29-0.52;P<.001),低风险组达到平均风险组45岁和50岁时累积发病率的年龄分别为51岁和58岁,提示低风险女性推迟乳腺X线筛查5至10年可能与新草案建议一致。
要点
- 低遗传风险组乳腺癌诊断风险显著低于平均风险组(HR 0.39;95%CI 0.29-0.52;P<.001)。
- 平均风险组45岁时0.69%被诊断乳腺癌,低风险组达到此比率在51岁。
- 平均风险组50岁时1.41%被诊断乳腺癌,低风险组达到此比率在58岁。
核心结论
- 该回顾性病例对照研究结果强调遗传学在个体化乳腺癌筛查起始时间中的价值。
- 通过在高风险和低风险策略中实施乳腺癌风险分层,可完善预防措施并优化医疗资源分配。
研究设计与样本
- 回顾性病例对照研究,纳入健康内华达项目2018至2022年间由Helix测序的25591名女性。
- 分析使用2022年底从电子健康记录提取的数据,平均可获取电子健康记录时长为12年,分析于2023年进行。
- 低风险遗传组分类需满足:BRCA1、BRCA2、PALB2、ATM或CHEK2无致病性变异或意义不明变异,且基于313个单核苷酸变异模型的多基因风险评分为低(最低10%)。
主要发现
- 25591名女性(平均[SD]年龄53.8[16.9]岁)中,2338名(9.1%)被分类为乳腺癌低风险,410名(1.6%)为高风险,22843名(89.3%)为平均风险。
- 低风险组乳腺癌诊断显著减少(风险比0.39;95%CI 0.29-0.52;P<.001)。
- 45岁时,平均风险组0.69%的女性被诊断乳腺癌,而低风险组达到此比率在51岁。
- 50岁时,平均风险组1.41%的女性被诊断乳腺癌,而低风险组达到此比率在58岁。
- 这些发现提示,对于乳腺癌低风险女性推迟乳腺X线筛查5至10年与新草案建议一致。
临床怎么用
- 原文结论指出遗传学在个体化乳腺癌筛查起始时间中具有价值。
- 作者认为通过在高风险和低风险策略中实施乳腺癌风险分层,可完善预防措施并优化医疗资源分配。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Genetic information is not being used to identify women at lower risk of breast cancer or other diseases in clinical practice. With the new US Preventive Services Task Force guidelines lowering the age for mammogram screening for all, there is a potential benefit in identifying women at lower risk of disease who may defer the start of mammographic screening. This genetic risk-based approach would help mitigate overscreening, associated costs, and anxiety. OBJECTIVE: To assess breast cancer incidence and age of onset among women at low genetic risk compared with women at average risk and evaluate the potential to delay mammography on the basis of genetic risk stratification. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case-control study included 25 591 women from the Healthy Nevada Project sequenced by Helix between 2018 and 2022. Data extracted from electronic health records at the end of 2022 (mean length of electronic health record available was 12 years) were used for the analysis in 2023. MAIN OUTCOMES AND MEASURES: Breast cancer diagnosis was identified from electronic health records. Classification to the low-risk genetic group required (1) the absence of pathogenic variants or a variant of uncertain significance in BRCA1, BRCA2, PALB2, ATM, or CHEK2, and (2) a low polygenic risk score (bottom 10%) using a 313-single-nucleotide variant model. RESULTS: Of 25 591 women in the study (mean [SD] age was 53.8 [16.9] years), 2338 women (9.1%) were classified as having low risk for breast cancer; 410 women (1.6%) were classified as high risk; and 22 843 women (89.3%) as average risk. There was a significant reduction in breast cancer diagnosis among the low-risk group (hazard ratio, 0.39; 95% CI, 0.29-0.52; P < .001). By 45 years of age, 0.69% of women in the average-risk group were diagnosed with breast cancer, whereas women in the low-risk group reached this rate at 51 years. By 50 years of age, 1.41% of those in the average-risk group were diagnosed with breast cancer, whereas those in the low-risk group reached this rate at age 58 years. These findings suggest that deferring mammogram screening by 5 to 10 years for women at low risk of breast cancer aligns with new draft recommendations. CONCLUSIONS AND RELEVANCE: The findings of this retrospective case-control study underscore the value of genetics in individualizing the onset of breast cancer screening. Improving breast cancer risk stratification by implementing both high-risk and low-risk strategies in screening can refine preventive measures and optimize health care resource allocation.
引用
- Bolze A, Cirulli ET, Hajek C, et al. The Potential of Genetics in Identifying Women at Lower Risk of Breast Cancer. JAMA Oncol. 2024. PMID: 38153744. doi:10.1001/jamaoncol.2023.5468
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。